Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""HYDROXYUREA"" wg kryterium: Temat


Tytuł :
Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome.
Autorzy :
Almeida SO; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson St, Torrance, CA, 90502, USA. Electronic address: .
Ram RJ; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 90095, USA.
Kinninger A; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson St, Torrance, CA, 90502, USA.
Budoff MJ; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson St, Torrance, CA, 90502, USA.
Pokaż więcej
Źródło :
Journal of cardiovascular computed tomography [J Cardiovasc Comput Tomogr] 2020 Jul - Aug; Vol. 14 (4), pp. 343-348. Date of Electronic Publication: 2020 Jan 17.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Acute Coronary Syndrome/*drug therapy
Adipose Tissue/*drug effects
Adiposity/*drug effects
Anti-Inflammatory Agents/*therapeutic use
Hydroxyurea/*analogs & derivatives
Lipoxygenase Inhibitors/*therapeutic use
Pericardium/*drug effects
Acute Coronary Syndrome/diagnostic imaging ; Acute Coronary Syndrome/physiopathology ; Adipose Tissue/diagnostic imaging ; Adipose Tissue/physiopathology ; Anti-Inflammatory Agents/adverse effects ; Canada ; Computed Tomography Angiography ; Double-Blind Method ; Female ; Humans ; Hydroxyurea/adverse effects ; Hydroxyurea/therapeutic use ; Lipoxygenase Inhibitors/adverse effects ; Male ; Middle Aged ; Pericardium/diagnostic imaging ; Pericardium/physiopathology ; Prospective Studies ; Time Factors ; Treatment Outcome ; United States
Czasopismo naukowe
Tytuł :
Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease.
Autorzy :
George A; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Dinu B; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Estrada N; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Minard CG; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
Hurwitz R; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Mahoney DH; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Yates AM; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Vaughan M; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Carmouche A; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Airewele G; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Kirk SE; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Fasipe T; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Uwaezuoke P; Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Ware RE; Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Sep; Vol. 95 (9), pp. E242-E244. Date of Electronic Publication: 2020 Jul 04.
Typ publikacji :
Letter; Randomized Controlled Trial
MeSH Terms :
Maximum Tolerated Dose*
Anemia, Sickle Cell/*drug therapy
Hydroxyurea/*administration & dosage
Adolescent ; Anemia, Sickle Cell/mortality ; Child ; Female ; Humans ; Hydroxyurea/adverse effects ; Male
Raport
Tytuł :
Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
Autorzy :
Galadanci NA; Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama.
Abdullahi SU; Department of Pediatrics, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Ali Abubakar S; Department of Radiology, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Wudil Jibir B; Department of Pediatrics, Hasiya Bayero Children's Hospital, Kano, Nigeria.
Aminu H; Murtala Mohammed Specialist Hospital, Kano, Nigeria.
Tijjani A; Murtala Mohammed Specialist Hospital, Kano, Nigeria.
Abba MS; Department of Pharmacy, Aminu Kano Teaching Hospital, Kano, Nigeria.
Tabari MA; Department of Radiology, Barau-Dikko Teaching Hospital, Kaduna, Nigeria.
Galadanci A; Department of Hematology, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Borodo AM; Department of Medicine, Murtala Muhammad Specialist Hospital, Kano, Nigeria.
Belonwu R; Department of Pediatrics, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Salihu AS; Department of Psychiatry, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Rodeghier M; Rodeghier Consultants, Chicago, Illinois.
Ghafuri DL; Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt-Meharry of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee.
Covert C Greene BV; Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt-Meharry of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee.
Neville K; Department of Pediatrics, Divisions of Pediatric Hematology-Oncology and Clinical Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Kassim AA; Division of Hematology and Oncology, Department of Medicine Vanderbilt University School of Medicine, Nashville, Tennessee.
Kirkham FJ; Department of Pediatrics, University College of London, Great Ormond Street Institute of Child Health, London, UK.
Jordan LC; Division of Pediatric Neurology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Aliyu MH; Vanderbilt Institute for Global Health, Nashville, Tennessee.
DeBaun MR; Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt-Meharry of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Sep; Vol. 95 (9), pp. E247-E250. Date of Electronic Publication: 2020 Jul 10.
Typ publikacji :
Clinical Trial; Letter; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anemia, Sickle Cell/*drug therapy
Hydroxyurea/*administration & dosage
Stroke/*prevention & control
Child ; Child, Preschool ; Female ; Humans ; Hydroxyurea/adverse effects ; Male ; Nigeria
Raport
Tytuł :
Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
Autorzy :
Ofakunrin AOD; Department of Paediatrics, College of Health Sciences, University of Jos/Jos University Teaching Hospital, Jos, Nigeria.
Oguche S; Department of Paediatrics, College of Health Sciences, University of Jos/Jos University Teaching Hospital, Jos, Nigeria.
Adekola K; Division of Hematology-Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Okpe ES; Department of Paediatrics, College of Health Sciences, University of Jos/Jos University Teaching Hospital, Jos, Nigeria.
Afolaranmi TO; Department of Community Medicine, College of Health Sciences, University of Jos/Jos University Teaching Hospital, Jos, Nigeria.
Diaku-Akinwumi IN; Department of Paediatrics, Lagos State University Teaching Hospital, Lagos, Nigeria.
Zoakah AI; Department of Community Medicine, College of Health Sciences, University of Jos/Jos University Teaching Hospital, Jos, Nigeria.
Sagay AS; Department of Obstetrics and Gynaecology, College of Health Sciences, University of Jos/Jos University Teaching Hospital, Jos, Nigeria.
Pokaż więcej
Źródło :
Journal of tropical pediatrics [J Trop Pediatr] 2020 Jun 01; Vol. 66 (3), pp. 290-298.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Anemia, Sickle Cell/*drug therapy
Antisickling Agents/*therapeutic use
Hydroxyurea/*therapeutic use
Adolescent ; Anemia, Sickle Cell/complications ; Anemia, Sickle Cell/epidemiology ; Antisickling Agents/administration & dosage ; Antisickling Agents/adverse effects ; Child ; Child, Preschool ; Female ; Hematocrit ; Humans ; Hydroxyurea/administration & dosage ; Hydroxyurea/adverse effects ; Infant ; Male ; Nigeria/epidemiology ; Stroke/etiology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
Autorzy :
Nickel RS; Division of Hematology, Children's National Hospital, Washington, DC; and.; The George Washington University School of Medicine and Health Sciences, Washington, DC.
Margulies S; Division of Hematology, Children's National Hospital, Washington, DC; and.
Frazer B; Division of Hematology, Children's National Hospital, Washington, DC; and.
Luban NLC; Division of Hematology, Children's National Hospital, Washington, DC; and.; The George Washington University School of Medicine and Health Sciences, Washington, DC.
Webb J; Division of Hematology, Children's National Hospital, Washington, DC; and.; The George Washington University School of Medicine and Health Sciences, Washington, DC.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Jun 18; Vol. 135 (25), pp. 2320-2322.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Blood Transfusion*/statistics & numerical data
Coronavirus Infections*
Pandemics*
Pneumonia, Viral*
Anemia, Sickle Cell/*therapy
Hydroxyurea/*administration & dosage
Adolescent ; Adult ; Anemia, Sickle Cell/complications ; Anemia, Sickle Cell/drug therapy ; Blood Donors/supply & distribution ; Blood Safety ; COVID-19 ; Chelation Therapy ; Child ; Child, Preschool ; Combined Modality Therapy ; Dose-Response Relationship, Drug ; Drug Monitoring ; Humans ; Hydroxyurea/adverse effects ; Hydroxyurea/therapeutic use ; Risk ; Secondary Prevention/methods ; Social Isolation ; Stroke/prevention & control ; Telemedicine ; Young Adult
Czasopismo naukowe
Tytuł :
Cognitive deficit in sickle cell disease: Is hydroxyurea part of the story?
Autorzy :
Hyacinth HI; Aflac Cancer and Blood Disorder Center of Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA.
Idris IM; Department of Haematology, Blood Transfusion Aminu Kano Teaching Hospital, Kano, Nigeria.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Jun; Vol. 189 (6), pp. 1014-1015. Date of Electronic Publication: 2020 Feb 24.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Anemia, Sickle Cell*/complications
Anemia, Sickle Cell*/drug therapy
Hydroxyurea*/adverse effects
Adolescent ; Antisickling Agents/adverse effects ; Cognition ; Humans
Czasopismo naukowe
Tytuł :
Effective use of hydroxyurea for sickle cell anemia in low-resource countries.
Autorzy :
Power-Hays A; Department of Pediatrics, Boston Medical Center.
Ware RE; Division of Hematology.; Global Health Center, Cincinnati Children's Hospital Medical Center.; University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Pokaż więcej
Źródło :
Current opinion in hematology [Curr Opin Hematol] 2020 May; Vol. 27 (3), pp. 172-180.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Anemia, Sickle Cell*/drug therapy
Anemia, Sickle Cell*/economics
Anemia, Sickle Cell*/epidemiology
Hydroxyurea*/economics
Hydroxyurea*/therapeutic use
Developing Countries/*economics
Africa South of the Sahara/epidemiology ; Caribbean Region/epidemiology ; Humans
Czasopismo naukowe
Tytuł :
[An 84-year-old man with an ulcer on his ankle].
Autorzy :
van Berkum-Zandkamp N; Deventer Ziekenhuis, afd. Dermatologie, Deventer.; Contact: Nicole van Berkum-Zandkamp ().
Houwing RH; Deventer Ziekenhuis, afd. Dermatologie, Deventer.
Sanders-Koers R; Deventer Ziekenhuis, afd. Dermatologie, Deventer.
Pokaż więcej
Transliterated Title :
Een 84-jarige man met een ulcus op zijn enkel.
Źródło :
Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2020 Apr 02; Vol. 164. Date of Electronic Publication: 2020 Apr 02.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Hydroxyurea*/administration & dosage
Hydroxyurea*/adverse effects
Skin Diseases*/chemically induced
Skin Diseases*/physiopathology
Skin Diseases*/therapy
Ulcer*/chemically induced
Ulcer*/physiopathology
Ulcer*/therapy
Ankle/*pathology
Hematologic Neoplasms/*drug therapy
Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Humans ; Long Term Adverse Effects/chemically induced ; Long Term Adverse Effects/therapy ; Male ; Pain/diagnosis ; Pain/etiology ; Treatment Outcome ; Withholding Treatment
Czasopismo naukowe
Tytuł :
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
Autorzy :
John CC; From the Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University, Indianapolis (C.C.J.); the Department of Pediatrics and Child Health, Makerere University (R.O.O., H.A.H., C.N., P.K., C.M.N.), Global Health Uganda (R.O.O., C.N.), and Mulago Hospital (P.K.) - all in Kampala, Uganda; the Division of Hematology, Department of Pediatrics (T.S.L., A.L., R.E.W.), and the Global Health Center (R.E.W.), Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine (A.L., R.E.W.) - all in Cincinnati; and the Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal (H.A.H.).
Opoka RO; From the Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University, Indianapolis (C.C.J.); the Department of Pediatrics and Child Health, Makerere University (R.O.O., H.A.H., C.N., P.K., C.M.N.), Global Health Uganda (R.O.O., C.N.), and Mulago Hospital (P.K.) - all in Kampala, Uganda; the Division of Hematology, Department of Pediatrics (T.S.L., A.L., R.E.W.), and the Global Health Center (R.E.W.), Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine (A.L., R.E.W.) - all in Cincinnati; and the Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal (H.A.H.).
Latham TS; From the Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University, Indianapolis (C.C.J.); the Department of Pediatrics and Child Health, Makerere University (R.O.O., H.A.H., C.N., P.K., C.M.N.), Global Health Uganda (R.O.O., C.N.), and Mulago Hospital (P.K.) - all in Kampala, Uganda; the Division of Hematology, Department of Pediatrics (T.S.L., A.L., R.E.W.), and the Global Health Center (R.E.W.), Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine (A.L., R.E.W.) - all in Cincinnati; and the Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal (H.A.H.).
Hume HA; From the Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University, Indianapolis (C.C.J.); the Department of Pediatrics and Child Health, Makerere University (R.O.O., H.A.H., C.N., P.K., C.M.N.), Global Health Uganda (R.O.O., C.N.), and Mulago Hospital (P.K.) - all in Kampala, Uganda; the Division of Hematology, Department of Pediatrics (T.S.L., A.L., R.E.W.), and the Global Health Center (R.E.W.), Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine (A.L., R.E.W.) - all in Cincinnati; and the Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal (H.A.H.).
Nabaggala C; From the Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University, Indianapolis (C.C.J.); the Department of Pediatrics and Child Health, Makerere University (R.O.O., H.A.H., C.N., P.K., C.M.N.), Global Health Uganda (R.O.O., C.N.), and Mulago Hospital (P.K.) - all in Kampala, Uganda; the Division of Hematology, Department of Pediatrics (T.S.L., A.L., R.E.W.), and the Global Health Center (R.E.W.), Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine (A.L., R.E.W.) - all in Cincinnati; and the Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal (H.A.H.).
Kasirye P; From the Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University, Indianapolis (C.C.J.); the Department of Pediatrics and Child Health, Makerere University (R.O.O., H.A.H., C.N., P.K., C.M.N.), Global Health Uganda (R.O.O., C.N.), and Mulago Hospital (P.K.) - all in Kampala, Uganda; the Division of Hematology, Department of Pediatrics (T.S.L., A.L., R.E.W.), and the Global Health Center (R.E.W.), Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine (A.L., R.E.W.) - all in Cincinnati; and the Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal (H.A.H.).
Ndugwa CM; From the Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University, Indianapolis (C.C.J.); the Department of Pediatrics and Child Health, Makerere University (R.O.O., H.A.H., C.N., P.K., C.M.N.), Global Health Uganda (R.O.O., C.N.), and Mulago Hospital (P.K.) - all in Kampala, Uganda; the Division of Hematology, Department of Pediatrics (T.S.L., A.L., R.E.W.), and the Global Health Center (R.E.W.), Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine (A.L., R.E.W.) - all in Cincinnati; and the Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal (H.A.H.).
Lane A; From the Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University, Indianapolis (C.C.J.); the Department of Pediatrics and Child Health, Makerere University (R.O.O., H.A.H., C.N., P.K., C.M.N.), Global Health Uganda (R.O.O., C.N.), and Mulago Hospital (P.K.) - all in Kampala, Uganda; the Division of Hematology, Department of Pediatrics (T.S.L., A.L., R.E.W.), and the Global Health Center (R.E.W.), Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine (A.L., R.E.W.) - all in Cincinnati; and the Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal (H.A.H.).
Ware RE; From the Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University, Indianapolis (C.C.J.); the Department of Pediatrics and Child Health, Makerere University (R.O.O., H.A.H., C.N., P.K., C.M.N.), Global Health Uganda (R.O.O., C.N.), and Mulago Hospital (P.K.) - all in Kampala, Uganda; the Division of Hematology, Department of Pediatrics (T.S.L., A.L., R.E.W.), and the Global Health Center (R.E.W.), Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine (A.L., R.E.W.) - all in Cincinnati; and the Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal (H.A.H.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Jun 25; Vol. 382 (26), pp. 2524-2533.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anemia, Sickle Cell/*drug therapy
Antisickling Agents/*administration & dosage
Hydroxyurea/*administration & dosage
Anemia, Sickle Cell/complications ; Antisickling Agents/adverse effects ; Child, Preschool ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Humans ; Hydroxyurea/adverse effects ; Incidence ; Malaria/epidemiology ; Male ; Peripheral Vascular Diseases/etiology ; Peripheral Vascular Diseases/prevention & control ; Prospective Studies ; Uganda
Czasopismo naukowe
Tytuł :
Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach.
Autorzy :
Kubick N; Department of Biochemistry and Molecular Cell Biology (IBMZ), University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Pajares M; Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain.
Enache I; Department of radiology, Victor Babes National Institute of Pathology, 99-101 Splaiul Independenței, 050096 Bucharest, Romania.
Manda G; Department of radiology, Victor Babes National Institute of Pathology, 99-101 Splaiul Independenței, 050096 Bucharest, Romania.
Mickael ME; PM forskningscentret, 17854 Ekerö Stockholm, Sweden.; Neuroimmunology group, Department of experimental Genomics, Institute of Animal Breeding and Genetics, Polish Academy of Science, Postępu 36A, 05-552 Garbatka, Poland.
Pokaż więcej
Źródło :
Molecules (Basel, Switzerland) [Molecules] 2020 May 05; Vol. 25 (9). Date of Electronic Publication: 2020 May 05.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-Inflammatory Agents/*pharmacology
Antidepressive Agents/*pharmacology
Hydroxyurea/*analogs & derivatives
Macrophages/*metabolism
Animals ; Artificial Intelligence ; Cells, Cultured ; Data Mining ; Drug Repositioning ; Hydroxyurea/pharmacology ; Lipopolysaccharides/adverse effects ; Macrophages/drug effects ; Mice ; NF-E2-Related Factor 2/metabolism ; Neural Networks, Computer ; RAW 264.7 Cells ; Semantics ; Sequence Analysis, RNA ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy.
Autorzy :
Roumenina LT; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Chadebech P; Etablissement Français du Sang, Ile-de-France, Hôpital Henri-Mondor, AP-HP, Créteil, France.; INSERM U955 équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est-Créteil (UPEC), Créteil, France; and Laboratoire d'excellence GR-Ex, Paris, France.
Bodivit G; Etablissement Français du Sang, Ile-de-France, Hôpital Henri-Mondor, AP-HP, Créteil, France.; INSERM U955 équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est-Créteil (UPEC), Créteil, France; and Laboratoire d'excellence GR-Ex, Paris, France.
Vieira-Martins P; Service d'Immunologie Biologique, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, AP-HP, Paris, France.
Grunenwald A; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Boudhabhay I; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Poillerat V; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Pakdaman S; Etablissement Français du Sang, Ile-de-France, Hôpital Henri-Mondor, AP-HP, Créteil, France.; INSERM U955 équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est-Créteil (UPEC), Créteil, France; and Laboratoire d'excellence GR-Ex, Paris, France.
Kiger L; INSERM U955 équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est-Créteil (UPEC), Créteil, France; and Laboratoire d'excellence GR-Ex, Paris, France.
Jouard A; Etablissement Français du Sang, Ile-de-France, Hôpital Henri-Mondor, AP-HP, Créteil, France.; INSERM U955 équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est-Créteil (UPEC), Créteil, France; and Laboratoire d'excellence GR-Ex, Paris, France.
Audureau E; Sickle Cell Referral Center, Service de Médecine Interne, Hôpital Henri-Mondor, AP-HP, Créteil, France.
Pirenne F; Etablissement Français du Sang, Ile-de-France, Hôpital Henri-Mondor, AP-HP, Créteil, France.; INSERM U955 équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est-Créteil (UPEC), Créteil, France; and Laboratoire d'excellence GR-Ex, Paris, France.
Galactéros F; INSERM U955 équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est-Créteil (UPEC), Créteil, France; and Laboratoire d'excellence GR-Ex, Paris, France.; Service de Santé Publique, Hôpital Henri-Mondor, AP-HP, Créteil, France.
Frémeaux-Bacchi V; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.; Service d'Immunologie Biologique, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, AP-HP, Paris, France.
Bartolucci P; INSERM U955 équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est-Créteil (UPEC), Créteil, France; and Laboratoire d'excellence GR-Ex, Paris, France.; Service de Santé Publique, Hôpital Henri-Mondor, AP-HP, Créteil, France.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 May; Vol. 95 (5), pp. 456-464. Date of Electronic Publication: 2020 Feb 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anemia, Sickle Cell/*therapy
Cell Count/*methods
Complement Activation/*genetics
Hemolysis/*physiology
Hydroxyurea/*therapeutic use
Adolescent ; Adult ; Female ; Humans ; Hydroxyurea/pharmacology ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł :
Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Autorzy :
Estcourt LJ; NHS Blood and Transplant, Haematology/Transfusion Medicine, Level 2, John Radcliffe Hospital, Headington, Oxford, UK, OX3 9BQ.
Kimber C; Systematic Review Initiative, NHS Blood and Transplant, Oxford, UK.
Hopewell S; University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Botnar Research Centre, Windmill Road, Oxford, Oxfordshire, UK, OX3 7LD.
Trivella M; University of Oxford, Centre for Statistics in Medicine, Botnar Research Centre, Windmill Road, Oxford, UK, OX3 7LD.
Doree C; NHS Blood and Transplant, Systematic Review Initiative, John Radcliffe Hospital, Oxford, UK, OX3 9BQ.
Abboud MR; American University of Beirut Medical Center, Department of Pediatrics and Adolescent Medicine, Beirut, Lebanon.
Pokaż więcej
Źródło :
The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2020 Apr 06; Vol. 4. Cochrane AN: CD012389. Date of Electronic Publication: 2020 Apr 06.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Erythrocyte Transfusion*
Phlebotomy*/adverse effects
Anemia, Sickle Cell/*complications
Antisickling Agents/*therapeutic use
Brain Infarction/*prevention & control
Hydroxyurea/*therapeutic use
Adolescent ; Anemia, Sickle Cell/drug therapy ; Antisickling Agents/adverse effects ; Brain Infarction/etiology ; Cause of Death ; Child ; Cognition/physiology ; Humans ; Hydroxyurea/adverse effects ; Primary Prevention/methods ; Quality of Life ; Randomized Controlled Trials as Topic ; Secondary Prevention/methods ; Stroke/prevention & control
Czasopismo naukowe
Tytuł :
Voxelotor: A Novel Treatment for Sickle Cell Disease.
Autorzy :
Herity LB; Virginia Commonwealth University Health System, Richmond, VA, USA.
Vaughan DM; Virginia Commonwealth University Health System, Richmond, VA, USA.
Rodriguez LR; Virginia Commonwealth University Health System, Richmond, VA, USA.
Lowe DK; Virginia Commonwealth University Health System, Richmond, VA, USA.
Pokaż więcej
Źródło :
The Annals of pharmacotherapy [Ann Pharmacother] 2021 Feb; Vol. 55 (2), pp. 240-245. Date of Electronic Publication: 2020 Jul 16.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anemia, Sickle Cell/*drug therapy
Benzaldehydes/*therapeutic use
Hematologic Agents/*therapeutic use
Pyrazines/*therapeutic use
Pyrazoles/*therapeutic use
Anemia, Sickle Cell/blood ; Benzaldehydes/administration & dosage ; Benzaldehydes/adverse effects ; Female ; Hematologic Agents/administration & dosage ; Hematologic Agents/adverse effects ; Hemoglobins/analysis ; Humans ; Hydroxyurea/administration & dosage ; Hydroxyurea/adverse effects ; Hydroxyurea/therapeutic use ; Male ; Pyrazines/administration & dosage ; Pyrazines/adverse effects ; Pyrazoles/administration & dosage ; Pyrazoles/adverse effects ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
Autorzy :
Costa E; Department of Pharmacy, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.; Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht, The Netherlands.
Tibalinda P; School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
Sterzi E; Department of Pharmacy, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Leufkens HMG; Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht, The Netherlands.
Makani J; Department of Haematology, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
Kaale E; School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
Luzzatto L; Department of Haematology, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Jan; Vol. 96 (1), pp. E2-E5. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anemia, Sickle Cell*/drug therapy
Anemia, Sickle Cell*/economics
Anemia, Sickle Cell*/epidemiology
Costs and Cost Analysis*
Antisickling Agents/administration & dosage ; Antisickling Agents/economics ; Female ; Humans ; Hydroxyurea/administration & dosage ; Hydroxyurea/economics ; Male ; Pilot Projects ; Tanzania/epidemiology
Czasopismo naukowe
Tytuł :
Hydroxyurea-induced Tooth Discoloration
Autorzy :
Okuyucu M; Ondokuz Mayıs University Faculty of Medicine, Department of Internal Medicine, Samsun, Turkey
Atay MH; Ondokuz Mayıs University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Samsun, Turkey
Pokaż więcej
Źródło :
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2020 Feb 20; Vol. 37 (1), pp. 74-75. Date of Electronic Publication: 2019 Nov 12.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Antineoplastic Agents/*adverse effects
Hydroxyurea/*adverse effects
Tooth Discoloration/*diagnosis
Tooth Discoloration/*etiology
Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Humans ; Hydroxyurea/therapeutic use ; Male ; Primary Myelofibrosis/complications ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/drug therapy
Raport
Tytuł :
Pharmaceutical analysis combined with in-silico therapeutic and toxicological profiling on zileuton and its impurities to assist in modern drug discovery.
Autorzy :
Ganorkar SB; Department of Pharmaceutical Chemistry, Central Instruments Facility (CIF), R. C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur, Dist: Dhule (MS), 425 405, India. Electronic address: .
Vander Heyden Y; Analytical Chemistry, Chemometrics and Molecular Modelling (FABI), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussel, Belgium. Electronic address: .
Shirkhedkar AA; Department of Pharmaceutical Chemistry, Central Instruments Facility (CIF), R. C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur, Dist: Dhule (MS), 425 405, India. Electronic address: .
Lokwani DK; Department of Pharmaceutical Chemistry, Central Instruments Facility (CIF), R. C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur, Dist: Dhule (MS), 425 405, India. Electronic address: .
Dhumal DM; Centre Interdisciplinaire de Nanoscience de Marseille (CINaM) CNRS UMR 7325, Aix-Marseille University. 163, Avenue Luminy, 13288, Marseille, France. Electronic address: .
Bobade PS; Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur. Electronic address: .
Pokaż więcej
Źródło :
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2020 Feb 05; Vol. 179, pp. 112982. Date of Electronic Publication: 2019 Nov 15.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Contamination*
Hydroxyurea/*analogs & derivatives
Arachidonate 5-Lipoxygenase/drug effects ; Chromatography, Liquid/methods ; Computer Simulation ; Drug Discovery/methods ; Hydrolysis ; Hydroxyurea/chemistry ; Hydroxyurea/therapeutic use ; Hydroxyurea/toxicity ; Magnetic Resonance Spectroscopy/methods ; Molecular Docking Simulation ; Molecular Structure ; Oxidative Stress ; Software ; Tandem Mass Spectrometry/methods
Czasopismo naukowe
Tytuł :
Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells.
Autorzy :
Gener P; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: .
Montero S; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain.
Xandri-Monje H; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
Díaz-Riascos ZV; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rafael D; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain.
Andrade F; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; INEB - Instituto Nacional de Engenharia Biomédica, Universidade do Porto,Porto, Portugal.
Martínez-Trucharte F; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
González P; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain.
Seras-Franzoso J; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
Manzano A; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arango D; Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sayós J; Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain; Immune Regulation and Immunotherapy, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
Abasolo I; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain. Electronic address: .
Schwartz S Jr; Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain. Electronic address: .
Pokaż więcej
Źródło :
Nanomedicine : nanotechnology, biology, and medicine [Nanomedicine] 2020 Feb; Vol. 24, pp. 102106. Date of Electronic Publication: 2019 Oct 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms*/drug therapy
Breast Neoplasms*/metabolism
Breast Neoplasms*/pathology
Micelles*
Neoplastic Cells, Circulating*/metabolism
Neoplastic Cells, Circulating*/pathology
Neoplastic Stem Cells*/metabolism
Neoplastic Stem Cells*/pathology
Hydroxyurea/*analogs & derivatives
Animals ; Female ; Humans ; Hydroxyurea/chemistry ; Hydroxyurea/pharmacology ; MCF-7 Cells ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease.
Autorzy :
Zahran AM; Department of Clinical Pathology, South Egypt Cancer Institute, Assiut, Egypt.
Nafady A; Faculty of Medicine, Department of Clinical Pathology, Assiut University, Assiut, Egypt.; Qena Faculty of Medicine, Department of Clinical and Chemical Pathology, South Valley University, Qena, Egypt.
Saad K; Faculty of Medicine, Department of Pediatrics, Assiut University, Assiut, Egypt.
Hetta HF; Faculty of Medicine, Department of Medical Microbiology and Immunology, Assiut University, Assiut, Egypt.
Abdallah AM; Faculty of Medicine, Department of Pediatrics, Assiut University, Assiut, Egypt.
Abdel-Aziz SM; Faculty of Medicine, Department of Pediatrics, Assiut University, Assiut, Egypt.
Embaby MM; Faculty of Medicine, Department of Pediatrics, Assiut University, Assiut, Egypt.
Abo Elgheet AM; Faculty of Medicine, Department of Pediatrics, Assiut University, Assiut, Egypt.
Darwish SF; Faculty of Pharmacy, Department of Microbiology, Cairo University, Cairo, Egypt.
Abo-Elela MGM; Faculty of Medicine, Department of Pediatrics, Assiut University, Assiut, Egypt.
Elhoufey A; Faculty of Nursing, Department of Community Health Nursing, Assiut University, Egypt.
Elsayh KI; Faculty of Medicine, Department of Pediatrics, Assiut University, Assiut, Egypt.
Pokaż więcej
Źródło :
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis [Clin Appl Thromb Hemost] 2020 Jan-Dec; Vol. 26, pp. 1076029619895111.
Typ publikacji :
Journal Article
MeSH Terms :
Anemia, Sickle Cell/*pathology
Hydroxyurea/*pharmacology
Inflammation/*diagnosis
Lymphocytes/*cytology
Neutrophils/*cytology
Adolescent ; Anemia, Sickle Cell/drug therapy ; Biomarkers/blood ; Cell Count ; Child ; Child, Preschool ; Cytokines/metabolism ; Female ; Humans ; Hydroxyurea/therapeutic use ; Inflammation/drug therapy ; Male ; Prognosis
Czasopismo naukowe
Tytuł :
Zileuton ameliorates depressive-like behaviors, hippocampal neuroinflammation, apoptosis and synapse dysfunction in mice exposed to chronic mild stress.
Autorzy :
Liu CH; Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China.
Tan YZ; Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China.
Li DD; Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China.
Tang SS; Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China.
Wen XA; Department of Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing 210009, China.
Long Y; Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China.
Sun HB; Department of Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing 210009, China.
Hong H; Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China. Electronic address: .
Hu M; Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China. Electronic address: .
Pokaż więcej
Źródło :
International immunopharmacology [Int Immunopharmacol] 2020 Jan; Vol. 78, pp. 105947. Date of Electronic Publication: 2019 Dec 01.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Antidepressive Agents/*therapeutic use
Depression/*drug therapy
Encephalitis/*drug therapy
Hydroxyurea/*analogs & derivatives
Neuroprotective Agents/*therapeutic use
Stress, Psychological/*drug therapy
Animals ; Anti-Inflammatory Agents/pharmacology ; Antidepressive Agents/pharmacology ; Apoptosis/drug effects ; Behavior, Animal/drug effects ; Depression/metabolism ; Depression/pathology ; Encephalitis/metabolism ; Encephalitis/pathology ; Hippocampus/drug effects ; Hippocampus/metabolism ; Hippocampus/pathology ; Hydroxyurea/pharmacology ; Hydroxyurea/therapeutic use ; Interleukin-1beta/metabolism ; Male ; Mice, Inbred ICR ; Neurogenesis/drug effects ; Neuroprotective Agents/pharmacology ; Stress, Psychological/metabolism ; Stress, Psychological/pathology ; Synapses/drug effects ; Transcription Factor RelA/metabolism ; Tumor Necrosis Factor-alpha/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies